Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL. Lukashev M, et al. Cancer Res. 2006 Oct 1;66(19):9617-24. doi: 10.1158/0008-5472.CAN-06-0217. Cancer Res. 2006. PMID: 17018619
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.
Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, Joseph I, Boccia A, Kelly R, Wortham K, Wang Q, Berquist L, Huang F, Gao SX, Zhang Y, Lugovskoy A, Martin S, Gouvis H, Berkowitz S, Chiang G, Reff M, Glaser SM, Hariharan K, Demarest SJ. Dong J, et al. J Biol Chem. 2011 Feb 11;286(6):4703-17. doi: 10.1074/jbc.M110.184317. Epub 2010 Dec 1. J Biol Chem. 2011. PMID: 21123183 Free PMC article.
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, Boccia A, Virata C, Gamez J, Yco G, Favis M, Wu X, Graff CP, Wang Q, Rohde E, Rennard R, Berquist L, Huang F, Zhang Y, Gao SX, Ho SN, Demarest SJ, Reff ME, Hariharan K, Glaser SM. Dong J, et al. Among authors: reff me. MAbs. 2011 May-Jun;3(3):273-88. doi: 10.4161/mabs.3.3.15188. Epub 2011 May 1. MAbs. 2011. PMID: 21393993 Free PMC article.
Future approaches for treating hematologic disease.
Reff M, Braslawsky G, Hanna N. Reff M, et al. Curr Pharm Biotechnol. 2001 Dec;2(4):369-82. doi: 10.2174/1389201013378626. Curr Pharm Biotechnol. 2001. PMID: 11762418 Review.
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A. Newman R, et al. Clin Immunol. 2001 Feb;98(2):164-74. doi: 10.1006/clim.2000.4975. Clin Immunol. 2001. PMID: 11161972
41 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page